This is a recording of the American Lung Association’s Lung Cancer Precision Medicine Summit which took place on June 18, 2020. Oncologists Dr. Erin Schenk and Dr. Ibiayi Dagogo-Jack discuss which precision medicine treatment is available for lung cancer patients and promising new research. Carly Ornstein, National Director of Lung Cancer Education, gives a high-level overview of precision medicine and discusses new resources. For more information visit Lung.org/biomarker-testing

This event was made possible by generous support from Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.

свернуть